Pharmafile.com’s weekly COVID-19 news round-up
pharmafile | October 14, 2020 | News story | Research and Development | COVID-19, coronavirus, covid news, pandemic, weekly roundup
The COVID-19 news this week focuses on FDA authorisations, with Eli Lilly seeking Emergency Use Authorization (EUA) from the FDA for its antibody therapy after releasing interim data based on early trial results, while Regeneron has announced that it has applied for an EUA for its own experimental antibody therapy that had been given to President Trump in his fight against coronavirus.
In other news, Tedros Adhanom Ghebreyesus, Director of the World Health Organization, has warned against pursuing a strategy of herd immunity to fight national COVID-19 outbreaks and newly released data has revealed that coronavirus has resulted in many more deaths than influenza or pneumonia in England and Wales throughout 2020.
1. GSK tells UK staff to turn off NHS COVID-19 tracking app while at work – Published 07/10/20
GlaxoSmithKline has told its employees to turn off the new NHS coronavirus tracking app at work as it could be disruptive to its business, according to The Guardian.
2. Head of WHO says herd immunity strategies for COVID-19 are ‘unethical’ – Published 13/10/20
Tedros Adhanom Ghebreyesus, Director of the World Health Organization, has warned against pursuing a strategy of herd immunity to fight national COVID-19 outbreaks.
3. Eli Lilly’s antibody COVID-19 therapy reduces virus levels and hospitalisations – Published 08/10/20
Eli Lilly is seeking Emergency Use Authorization from the FDA after releasing interim data based on early trial results.
4. COVID-19 has caused over three times more deaths than flu or pneumonia in England and Wales – Published on 08/10/20
Newly released data has revealed that COVID-19 has resulted in many more deaths than influenza or pneumonia in England and Wales throughout 2020, it has been reported.
5. Regeneron applies for FDA Emergency Use Authorization for COVID-19 antibody treatment given to Trump – Published 08/10/20
Regeneron has announced that it has applied for an Emergency Use Authorization from the FDA for its experimental antibody therapy that has been given to President Trump in his fight against coronavirus.
Conor Kavanagh
Related Content
Gilead’s Veklury recommended by NICE for COVID-19 treatment
Gilead Sciences has announced that the National Institute of Health and Care Excellence (NICE) has …
NICE expands access to Paxlovid for 1.4 million people at risk of severe COVID-19
The National Institute for Health and Care Excellence (NICE) has announced that it has expanded …
Moderna shares data from phase 1/2 trial for combination flu and COVID-19 vaccine
Moderna has announced positive interim results from the phase 1/2 trial of mRNA-1083, its investigational …
